NICE technology appraisal guidance
Issued: September 2008
TA157

Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta157

1 Guidance

1.1 Dabigatran etexilate, within its marketing authorisation, is recommended as an option for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip replacement surgery or elective total knee replacement surgery.